7th CKD3 Summit 2025 - Brochure

With Novartis creating Borealis Biosciences and gaining approval for their IgAN therapy along with Travere Therapeutics, Otsuka’s success in phase III interim analysis, Apellis and Sobi’s phase III trial success, Judo Bio launching with $100M, Biogen acquiring HIBio for $1.15B, Vertex acquiring Alpine Immune Sciences for $4.9B and the FDA’s support of accelerated pathways for treatments... It’s safe to say 2024 has been filled with unprecedented excitement and innovation for chronic kidney diseases and we are well and truly in the kidney renaissance, the transformative era of renal drug development.